<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">EPOPROSTENOL SODIUM <img border="0" src="../images/pr.gif"/></span><br/>(e-po-pros'te-nol)<br/><span class="topboxtradename">Flolan<br/></span><b>Classifications:</b> <span class="classification">prostaglandin</span>; <span class="classification">antihypertensive</span>; <span class="classification">antiplatelet agent</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.5 mg, 1.5 mg powder for injection</p>
<h1><a name="action">Actions</a></h1>
<p>Naturally occurring prostaglandin. Reduces right and left ventricular afterload, increases cardiac output, and increases stroke
         volume through its vasodilation effect. May also decrease pulmonary vascular resistance and mean systemic arterial pressure,
         depending on the dose.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Potent vasodilator of pulmonary and systemic arterial vascular beds and an inhibitor of platelet aggregation.</p>
<h1><a name="uses">Uses</a></h1>
<p>Long-term treatment of primary pulmonary hypertension in NYHA Class III and IV patients.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Chronic use with CHF patients, hypersensitivity to epoprostenol or related compounds.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Older adults, pregnancy (category B), lactation. Safety and efficacy in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Primary Pulmonary Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span>
<i>Acute dose,</i> Initiate with 2 ng/kg/min, increase by 2 ng/ kg/min q15 min until dose-limiting effects occur (e.g., nausea, vomiting, headache, hypotension, flushing); <i>Chronic administration,</i> Start infusion at 4 ng/kg/min less than the maximum tolerated infusion; if maximum tolerated infusion is <img src="../images/special/lesserorequal.gif"/>5
               ng/kg/min, start maintenance infusion at 50% of maximum tolerated dose<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: Anticoagulation therapy is generally initiated along with epoprostenol.
            			
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Continuous:</span> Must be reconstituted using sterile diluent for epoprostenol; must not be mixed with any other medications or solution prior
                  to or during administration. To make 100 mL of 3000 ng/mL, add 5 mL of diluent to one 0.5 mg vial; withdraw 3 mL and add to
                  enough diluent to make a total of 100 mL. To make 100 mL of 5000 ng/mL, add 5 mL of diluent to one 0.5 mg vial; withdraw contents
                  of vial and add to enough diluent to make a total of 100 mL. To make 100 mL of 10,000 ng/mL, add 5 mL of diluent to each of
                  two 0.5 mg vials; withdraw contents of each vial and add to enough diluent to make a total of 100 mL. To make 100 mL of 15,000
                  ng/mL, add 5 mL of diluent to a 1.5 mg vial; withdraw contents of vial and add to enough diluent to make a total of 100 mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Continuous:</span> Give at ordered rate using an infusion control device. Avoid abrupt infusion interruption or large dosage reduction.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span> Do not mix or infuse with any other drugs. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store unopened vials at 15°25° C (59°77° F). Protect from light. See manufacturer's directions
            for stability or storage of reconstituted solutions.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Chills, fever, flu-like syndrome, dizziness,</span> syncope, <span class="speceff-common">headache, anxiety/nervousness,</span> hyperesthesia, paresthesia, dizziness. <span class="typehead">CV:</span>
<span class="speceff-common">Tachycardia, hypotension, flushing, chest pain,</span> bradycardia. <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea, nausea, vomiting,</span> abdominal pain. <span class="typehead">Musculoskeletal:</span>
<span class="speceff-common">Jaw pain, myalgia, nonspecific musculoskeletal pain.</span>
<span class="typehead">Respiratory:</span> Dyspnea. <span class="typehead">Other:</span> Dose-limiting effects. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Hypotension if administered with other <span class="classification">vasodilators</span> or <span class="classification">antihypertensives</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Peak:</span>  Approximately 15 min. <span class="typehead">Metabolism:</span> Rapidly hydrolyzed at neutral pH in blood; also subject to enzyme degradation. <span class="typehead">Elimination:</span> 82% eliminated in urine. <span class="typehead">Half-Life:</span> Approximately 6 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess carefully for development of pulmonary edema during dose ranging.</li>
<li>Monitor respiratory and cardiovascular status frequently during entire period of chronic use of epoprostenol.</li>
<li>Monitor for and report recurrence or worsening of symptoms associated with primary pulmonary hypertension (e.g., dyspnea,
            dizziness, exercise intolerance) or adverse effects of drug; dosage adjustments may be needed.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn correct techniques for storage, reconstitution, and administration of drug, and maintenance of catheter site (see <small>ADMINISTRATION</small>).
         </li>
<li>Notify physician immediately of S&amp;S of worsening primary pulmonary hypertension, adverse drug reactions, and S&amp;S of infection
            at catheter site or sepsis.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>